Palvella Launches BEYOND mLM Campaign for 30,000 US Patients
Palvella Therapeutics has launched the BEYOND mLM disease awareness campaign and BEYONDmLM.com to educate patients, caregivers, and healthcare professionals about microcystic lymphatic malformations, affecting over 30,000 diagnosed individuals in the US with no FDA-approved treatments. The campaign partners with five leading nonprofit organizations to bolster community engagement and support.
1. Campaign Launch and Website
Palvella Therapeutics introduced the BEYOND mLM initiative and the accompanying BEYONDmLM.com site to provide accessible, evidence-based information on microcystic lymphatic malformations. The platform features educational content designed to improve disease understanding, facilitate care navigation, and empower patients, caregivers, and healthcare professionals.
2. Nonprofit Collaboration
The campaign is developed in collaboration with five nonprofit organizations: Consortium of iNvestigators of Vascular AnomalieS (CaNVAS), Lymphangiomatosis & Gorham’s Disease Alliance (LGDA), Lymphatic Education & Research Network (LE&RN), Pediatric Dermatology Research Alliance (PeDRA), and VAccess.org. These partners contribute expertise in advocacy, research, and patient support to enhance the campaign’s reach and credibility.
3. Market Opportunity and Patient Impact
Microcystic lymphatic malformations affect an estimated 30,000 patients in the United States and currently have no FDA-approved therapies. By raising disease awareness and strengthening community networks, Palvella aims to pave the way for its QTORIN™ rapamycin gel and future clinical programs targeting this underserved patient population.